title: Synthesis and pharmacological evaluation of 6-naltrexamine analogs for alcohol cessation.
abstract: A series of substituted aryl amide derivatives of 6-naltrexamine, 3 designed to be metabolically stable were synthesized and used to characterize the structural requirements for their potency to binding and functional activity of human mu (mu), delta (delta) and kappa (kappa) opioid and nociceptin (NOP) receptors. Binding assays showed that 4-10 had subnanomolar K(i) values for mu and kappa opioid receptors. Functional assays for stimulation of [(35)S]GTPgammaS binding showed that several compounds acted as partial or inverse agonists and antagonists of the mu and delta, kappa opioid or NOP receptors. The compounds showed considerable stability in the presence of rat, mouse or human liver preparations and NADPH. The inhibitory activity on the functional activity of human cytochrome P450s was examined to determine any potential inhibition by 4-9. Only modest inhibition of CYP3A4, CYP2C9 and CYP2C19 was observed for a few of the analogs. As a representative example, radiolabeled 6 was examined in vivo and showed reasonable brain penetration. The inhibition of ethanol self-administration in rats trained to self-administer a 10% (w/v) ethanol solution, utilizing operant techniques showed 5-8 to have very potent efficacy (ED(50) values 19-50 microg/kg).
authors.affiliation: Human BioMolecular Research Institute, 5310 Eastgate Mall, San Diego, CA 92121, USA.
authors.forename: Senait
authors.initials: S
authors.lastname: Ghirmai
authors.forename: Marc R
authors.initials: MR
authors.lastname: Azar
authors.forename: John R
authors.initials: JR
authors.lastname: Cashman
mesh_terms: D000427:Alcohol Deterrents / Q000737:chemistry* / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D000437:Alcoholism / Q000188:drug therapy*; D000818:Animals; D006801:Humans; D008099:Liver / Q000378:metabolism; D008297:Male; D051379:Mice; D009271:Naltrexone / Q000031:analogs & derivatives* / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D011485:Protein Binding; D051381:Rats; D017208:Rats, Wistar; D011957:Receptors, Opioid / Q000378:metabolism*; D017465:Receptors, Opioid, delta / Q000378:metabolism; D017473:Receptors, Opioid, kappa / Q000378:metabolism; D017450:Receptors, Opioid, mu / Q000378:metabolism; D013329:Structure-Activity Relationship; D000094942:Nociceptin Receptor
chemical_list: D000427:Alcohol Deterrents; D011957:Receptors, Opioid; D017465:Receptors, Opioid, delta; D017473:Receptors, Opioid, kappa; D017450:Receptors, Opioid, mu; D009271:Naltrexone; C035438:beta-naltrexamine; D000094942:Nociceptin Receptor
references.citation: Addiction. 2004 Jul;99(7):811-28
references.pmid: 15200577
references.citation: Alcohol Clin Exp Res. 1998 Dec;22(9):2174-85
references.pmid: 9884166
references.citation: Life Sci. 1983 Jan 17;32(3):197-204
references.pmid: 6296588
references.citation: J Med Chem. 2000 Jul 13;43(14):2759-69
references.pmid: 10893314
references.citation: Neuropsychopharmacology. 2006 Jul;31(7):1489-99
references.pmid: 16237389
references.citation: J Med Chem. 2006 Nov 30;49(24):6987-7001
references.pmid: 17125252
references.citation: Curr Top Med Chem. 2005;5(6):585-94
references.pmid: 16022681
references.citation: J Biol Chem. 1981 Oct 10;256(19):10017-23
references.pmid: 6268622
references.citation: Neuropsychopharmacology. 2008 Feb;33(3):643-52
references.pmid: 17473837
references.citation: Psychopharmacology (Berl). 1999 Aug;145(4):360-9
references.pmid: 10460312
references.citation: Am J Psychiatry. 1999 Nov;156(11):1758-64
references.pmid: 10553740
references.citation: Alcohol. 1993 Mar-Apr;10(2):127-32
references.pmid: 8095143
references.citation: J Med Chem. 2004 Nov 4;47(23):5809-15
references.pmid: 15509180
references.citation: Eur Neuropsychopharmacol. 2006 Jul;16(5):311-23
references.pmid: 16361086
references.citation: Alcohol Clin Exp Res. 1997 Aug;21(5):784-91
references.pmid: 9267526
references.citation: J Med Chem. 2008 Mar 27;51(6):1913-24
references.pmid: 18298057
references.citation: Addict Biol. 2006 Sep;11(3-4):397-403
references.pmid: 16961767
references.citation: Arch Gen Psychiatry. 1997 Dec;54(12):1130-5
references.pmid: 9400350
references.citation: Drug Metab Dispos. 1997 Aug;25(8):1001-7
references.pmid: 9280409
references.citation: Arch Gen Psychiatry. 1999 Aug;56(8):719-24
references.pmid: 10435606
references.citation: Am J Clin Nutr. 1985 Nov;42(5 Suppl):1099-132
references.pmid: 2865892
references.citation: Brain Res. 1993 Sep 3;621(1):137-40
references.pmid: 7693299
references.citation: J Pharmacol Exp Ther. 2000 Jun;293(3):1002-8
references.pmid: 10869404
references.citation: Psychopharmacology (Berl). 1997 Jan;129(2):99-111
references.pmid: 9040115
references.citation: J Med Chem. 2009 Mar 12;52(5):1416-27
references.pmid: 19199782
references.citation: Neurosci Biobehav Rev. 2002 Oct;26(6):713-28
references.pmid: 12479844
references.citation: Arch Gen Psychiatry. 1996 Mar;53(3):250-7
references.pmid: 8611062
references.citation: Biochem Pharmacol. 1973 Dec 1;22(23):3099-108
references.pmid: 4202581
references.citation: J Clin Psychiatry. 1995;56 Suppl 7:5-14
references.pmid: 7673105
references.citation: Biochem Pharmacol. 2004 Feb 15;67(4):751-6
references.pmid: 14757175
references.citation: Alcohol. 2001 Feb;23(2):109-16
references.pmid: 11331108
references.citation: Alcohol Clin Exp Res. 1999 Sep;23(9):1468-76
references.pmid: 10512312
references.citation: Drug Metab Rev. 2006;38(4):641-9
references.pmid: 17145693
references.citation: Neuropsychopharmacology. 2003 Aug;28(8):1463-71
references.pmid: 12700689
references.citation: Drug Metab Rev. 1984;15(5-6):1163-82
references.pmid: 6396055
references.citation: Mol Pharmacol. 1995 Apr;47(4):848-54
references.pmid: 7723747
references.citation: J Biol Chem. 1989 Feb 5;264(4):1988-97
references.pmid: 2914890